Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUR 106

Next Previous
Drug Profile

AUR 106

Alternative Names: AUR-106

Latest Information Update: 03 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 17 Apr 2026 Aurigene Discovery Technologies Limited terminates a phase I trial in Cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in India due to patient recruitment problems (PO) (NCT05861947)
  • 26 Aug 2023 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in India (PO), (NCT05861947)
  • 17 May 2023 Aurigene Discovery Technologies Limited plans a phase I trial for Solid tumours (Second-line therapy or greater, Late stage disease) in India (PO), in May 2023 (NCT05861947)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top